{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:13:29Z","timestamp":1791213209123,"version":"4.1.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T00:00:00Z","timestamp":1390521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0086194","type":"journal-article","created":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T21:34:09Z","timestamp":1390599249000},"page":"e86194","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":44,"title":["Survival According to BRAF-V600 Tumor Mutations \u2013 An Analysis of 437 Patients with Primary Melanoma"],"prefix":"10.1371","volume":"9","author":[{"given":"Diana","family":"Meckbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Pflugfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Eigentler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Capper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"von Deimling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Mittelbronn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Perner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Ikenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hantschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Weide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,1,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"H Davies","year":"2002","journal-title":"Nature"},{"key":"ref2","first-page":"756","article-title":"Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation","volume":"63","author":"K Satyamoorthy","year":"2003","journal-title":"Cancer Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"KT Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"PB Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"KT Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2011.06.056","article-title":"Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort","volume":"48","author":"L Si","year":"2012","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"GV Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"AM Menzies","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"JA Jakob","year":"2012","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-3163-3-6","article-title":"Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis","volume":"3","author":"R Houben","year":"2004","journal-title":"J Carcinog"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/annonc\/mdr126","article-title":"First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50\/07)","volume":"23","author":"R von Moos","year":"2012","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing","volume":"16","author":"E Edlundh-Rose","year":"2006","journal-title":"Melanoma Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/jid.2012.283","article-title":"BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma","volume":"133","author":"GJ Mann","year":"2013","journal-title":"J Invest Dermatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1245\/s10434-012-2457-5","article-title":"Prognostic value of BRAF(V(6)(0)(0)) mutations in melanoma patients after resection of metastatic lymph nodes","volume":"19","author":"S Moreau","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/1078-0432.CCR-10-2276","article-title":"Clinical correlates of NRAS and BRAF mutations in primary human melanoma","volume":"17","author":"JA Ellerhorst","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jnci\/djg123","article-title":"Determinants of BRAF mutations in primary melanomas","volume":"95","author":"JL Maldonado","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/1078-0432.CCR-1169-3","article-title":"Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas","volume":"10","author":"M Shinozaki","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.0022-202X.2005.23788.x","article-title":"BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival","volume":"125","author":"LA Akslen","year":"2005","journal-title":"J Invest Dermatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1479-5876-2-46","article-title":"Clinical significance of BRAF mutations in metastatic melanoma","volume":"2","author":"DZ Chang","year":"2004","journal-title":"J Transl Med"},{"key":"ref20","first-page":"3362","article-title":"BRAF mutations in metastatic melanoma: a possible association with clinical outcome","volume":"9","author":"R Kumar","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e47054","DOI":"10.1371\/journal.pone.0047054","article-title":"The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis","volume":"7","author":"G Safaee Ardekani","year":"2012","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/CMR.0b013e328335a8dd","article-title":"Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment","volume":"20","author":"KG Lasithiotakis","year":"2010","journal-title":"Melanoma Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1200\/JCO.2010.31.5812","article-title":"Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database","volume":"29","author":"JF Thompson","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"CM Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"19","author":"CM Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis","volume":"164","author":"JH Lee","year":"2011","journal-title":"Br J Dermatol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1055-9965.EPI-06-1038","article-title":"Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma","volume":"16","author":"NE Thomas","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jmoldx.2012.10.002","article-title":"Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma","volume":"15","author":"WO Greaves","year":"2013","journal-title":"J Mol Diagn"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"M Colombino","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-011-0887-y","article-title":"Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases","volume":"123","author":"D Capper","year":"2012","journal-title":"Acta Neuropathol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"CM Balch","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0086194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T12:50:28Z","timestamp":1648126228000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0086194"}},"subtitle":[],"editor":[{"given":"Nikolas K.","family":"Haass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0086194","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,24]]}}}